Actor portrayal

VYNDAMAX works by slowing the break down and build up of dangerous TTR deposits

ATTR-CM happens when a protein called transthyretin (TTR) breaks down and turns into amyloid. Amyloid can build up in the heart making it harder for the heart to pump effectively.

The TTR protein is mostly made in the liver and in smaller amounts in the outer lining of the brain and retina.

Illustration depicting VYNDAMAX (tafamidis) attaching to the ttr protein. See safety information.

Attach

VYNDAMAX attaches to the TTR protein.

Illustration depicting VYNDAMAX (tafamidis) stabilizing ttr after attaching to the protein. See safety info.

Stabilize

VYNDAMAX stabilizes TTR, helping it stay together.

A heart icon symbolizing VYNDAMAX (tafamidis) stabilizing ttr, slowing the breakdown and buildup of dangerous deposits and slowing the progression of ATTR-CM. See safety info.

Maintain

By stabilizing TTR, VYNDAMAX slows the breakdown and buildup of dangerous deposits, which can help to slow the progression of ATTR-CM.

VYNDAMAX works by binding to the TTR protein, stabilizing it, and preventing it from breaking down

CARDIOLOGIST RECOMMENDED

VYNDAMAX is a treatment with a Class 1* recommendation for ATTR-CM in guidelines from:

  • American College of Cardiology

  • American Heart Association

  • Heart Failure Society of America

*Class 1 guidelines are given when there’s strong evidence or general agreement that a treatment is beneficial, useful, and effective. The above recommendation is from the 2022 guidelines.

Questions to ask your doctor

  • What causes ATTR-CM to develop?
  • Could my heart failure diagnosis and other symptoms be ATTR-CM?
  • If so, what are the next steps we should take to determine if I have ATTR-CM?
  • If I have ATTR-CM, could VYNDAMAX be right for me?

Create a discussion guide to help you log your symptoms and talk to your doctor about ATTR-CM

Get started

Read about talking to your doctor